New cancer pill enters first human tests

NCT ID NCT07363967

Recruiting now Disease control Sponsor: Beijing StoneWise Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called SWA1211, taken as a daily tablet, in 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors. Because this is the first time SWA1211 is being tested in humans, the focus is on safety and tolerability, not yet on effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SWA1211 (an experimental drug taken as a tablet by mouth once daily)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) and small (60 people) study focused on safety and dosing. It is too soon to know if SWA1211 will shrink tumors or have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.